Technology
Health
Biotechnology
Cytokinetics
$8.759876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$8.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.09 (-1.02%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Cytokinetics and other stocks, options, ETFs, and crypto commission-free!
About
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Employees
130
Headquarters
South San Francisco, California
Founded
1997
Market Cap
483.71M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
375.98K
High Today
$9.24
Low Today
$8.71
Open Price
$8.91
Volume
228.79K
52 Week High
$10.44
52 Week Low
$5.75
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America
News
The Motley FoolMar 20
Here's Why Cytokinetics Stock Jumped Today
What happened Shares of Cytokinetics (NASDAQ:CYTK), a clinical-stage biopharmaceutical company, jumped in afternoon trading after its partner, Amgen (NASDAQ:AMGN), reported some good news. An improved outlook for Cytokinetics' lead candidate drove the stock 19% higher on Wednesday. So what Cytokinetics and Amgen have been working on new heart failure drugs since 2006, and omecamtiv mecarbil, the most advanced new drug candidate they've produced so far, took another step toward commercialization today. A...
Seeking AlphaMar 20
Large-scale study of Cytokinetics' omecamtiv mecarbil to continue unmodified
Cytokinetics (NASDAQ:CYTK) and collaboration partner Amgen (NASDAQ:AMGN) announce that their large-scale Phase 3 clinical trial, GALACTIC-HF, evaluating cardiac myosin activator omecamtiv mecarbil in ~8,000 heart failure patients will continue unchanged.
Markets InsiderMar 20
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, March 20, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtivmecarbil continue without ch...
Price Paid on Robinhood
7% Lower
Right Now
52 Week Low
$5.75
Average Price Paid
$9.41
52 Week High
$10.44
Earnings
-$0.75
-$0.63
-$0.52
-$0.40
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 25, After Hours